A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT04714320

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04714320
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04714320. Randomized; no masking; primary purpose treatment. Start 2021-04-28 (actual); primary completion 2022-06-29 (actual). Results posted on 2025-02-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
Acronym
ASTRAAS
Condition
Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
IONIS-AGT-LRx
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04714320
Content hash
65b5de0eab25877ae82cf9bc789d3cb992906f7b538f166ec03937d8ea5aaad2